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Active pharmaceutical ingredients (APIs) can enter the natural environment
during manufacture, use and/or disposal, and consequently public concern
about their potential adverse impacts in the environment is growing. Despite
the bulk of the human population living in Asia and Africa (mostly in low- or
middle-income countries), limited work relating to research, development
and regulations on APIs in the environment have so far been conducted in
these regions. Also, the API manufacturing sector is gradually shifting to
countries with lower production costs. This paper focuses mainly on APIs
for human consumption and highlights key differences between the low-,
middle- and high-income countries, covering factors such as population
and demographics, manufacture, prescriptions, treatment, disposal and
reuse of waste and wastewater. The striking differences in populations
(both human and animal), urbanization, sewer connectivity and other factors
have revealed that the environmental compartments receiving the bulk of
API residues differ markedly between low- and high-income countries.
High sewer connectivity in developed countries allows capture and treatment
of the waste stream (point-source). However, in many low- or middle-income
countries, sewerage connectivity is generally low and in some areas waste is
collected predominantly in septic systems. Consequently, the diffuse-source
impact, such as on groundwater from leaking septic systems or on land
due to disposal of raw sewage or septage, may be of greater concern. A
screening level assessment of potential burdens of APIs in urban and rural
environments of countries representing low- and middle-income as well as
high-income has been made. Implications for ecological risks of APIs used
by humans in lower income countries are discussed.1. Introduction
Public concerns about the potential adverse impact of active pharmaceutical
ingredient (API) residues in the environment have increased during the past
decade. In addition to sub-lethal effects, such as in the case of endocrine disrup-
tion in fish [1,2], direct toxic effects of APIs on exposed organisms, with
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2population level impacts, have been noted. Exposure to resi-
dues of the non-steroidal anti-inflammatory drug (NSAID)
diclofenac in tissues of cattle in Asia resulted in massive
declines (more than 95%) in the populations of some species
of vultures in Asia [3]. As a result, diclofenac was withdrawn
from veterinary use in India [4,5]. The ‘Asian vulture crisis’,
provides an example of an unexpected acute exposure route
that highlighted the potential ecological impact of these bio-
logically active compounds. Another area of concern relates
to ecological risks associated with environmental contamin-
ation by antibiotics, with potential for direct toxicity to
aquatic microorganisms and indirect impacts through prolifer-
ation of antibiotic resistance [6]. Despite these examples, there
has been a notable lack of studies that demonstrate effects of
APIs based on ecologically relevant assessments, with respect
to appropriate exposure concentrations and duration, ecotoxi-
cological endpoints and implications of mixture effects [7,8].
However, where ecologically appropriate exposures were
used, APIs have been demonstrated to cause effects in organ-
isms, such as behaviour and reproduction, which may have
broader ecological consequences [7,9–14].
APIs used to treat diseases in humans (and animals) can
enter the natural environment during the manufacturing pro-
cess [15] or, following therapeutic use, via some form of
wastewater collection and treatment system [16]. The excretion
or application of animal manures to agricultural land or water-
ways occur following veterinary/aquaculture use [17,18].
Generally, wastewater undergoes some level of treatment
which can be variably effective in removing APIs. However,
discharges of high concentrations of APIs in the environment
may occur due to lack or inefficiency of treatment facilities
or inappropriate disposal practices. A range of APIs have
been detected in different environmental compartments over
the years [19–22]. Some of these compounds (e.g. carbamaze-
pine, fluoxetine, fluroquinolones and tetracycline antibiotics)
may persist in the environment [23]. Consequently, increasing
attention is being placed globally on the impacts of APIs that
are present in the environment.
Despite the fact that a vast majority of the human popu-
lation live in Asia and Africa, the majority of research
(75%) and most of the regulatory developments on APIs
in the environment have focused on the North American
and European situations [20]. A significant amount of work
has also been done in some Asian countries (e.g. China,
Japan and South Korea). However, much less information is
available for other regions of the world such as Oceania,
Africa, South America and parts of Asia. In addition to the
huge population pressure in these regions, there has been a
gradual shift in the global API manufacturing sector over
recent years due to outsourcing of drug manufacturing to
lower income countries [24].
A number of factors will determine the environmental
exposure of an API including: (i) population and demo-
graphics, (ii) access to health systems, (iii) size and nature of
the manufacturing sector, (iv) connectivity to sewerage and
sewage treatment systems, (v) ecology of the receiving
environment and (vi) the availability and effectiveness of regu-
latory frameworks. These factors are likely to differ between
high- and lower income economies, and consequently as are
the environmental risks of APIs.
In this paper, we examine the key differences between
some of the above risk factors relating to environmental
exposure in low-, middle- (e.g. in Asia, South America) andhigh-income countries (e.g. from Australasia, North America
and Europe). We initially consider differences in factors driv-
ing the use of APIs and their release into the environment,
then move on to discuss differences in pathways into the
environment and the evidence for environmental contamin-
ation by APIs in lower income countries. Finally, we make a
relative assessment of the likely differences in factors among
selected low-, middle- and high-income countries contributing
to the environmental risk of APIs. As published data relating
to the presence of APIs in the aquatic environment have been
dominated by research from Europe and North America
[8,20,25], this paper focuses on low- and middle-income
countries as a means of comparing and contrasting with
high-income countries, the factors which can influence the
level of API residues in the environment. We provide selected
examples of sources and pathways of exposure and effects
of human APIs on ecosystem health to illustrate the most
important differences between low- and high-income nations.2. Key contributing factors to ecological risks
associated with active pharmaceutical
ingredients in lower income countries
(a) Population and demographics
One of the key factors governing the total demand for APIs is
the size of the human population of a country and the acces-
sibility to healthcare. Some of the world’s most populous
countries are located in growing economies in the continents
of Asia, Africa and South America (electronic supplementary
material, table S1). Here, the contrast is the greatest between
low- to middle- and high-income nations. Nearly 78% of the
total global population is located in Asia and Africa, whereas
only about 16% is present in Europe and North America.
Indeed, nearly 40% of the global population lives in
three Asian countries, namely China, India and Indonesia
(electronic supplementary material, table S1).
On the basis of concentration of human population, one
would assume that the overall demand for APIs would be
higher in Asia and consequently expect a greater environ-
mental risk from a greater presence of APIs. The population
pressure (or lack of it) does not, however, directly translate
into environmental impact as there are other factors that
can moderate it. For example, the population density of Aus-
tralia is low but most of the population is congregated in
cities, leading to the concentration of waste streams. Simi-
larly, 13 of the 100 most populated urban agglomerations in
the world are located in South America (eight in Brazil)
with more than 3.5 million people in each of these. The
degree of urbanization (electronic supplementary material,
table S1) may be a good indicator of areas where discharge
of APIs to the environment is likely to be concentrated.
Age demographic is an important factor in determining
demand for pharmaceuticals. While the per capita demand
for medication increases with increasing age, the overall use
of APIs is a complex phenomenon. Not only the amount
but also the combination of particular pharmaceuticals that
are used are expected to be different for the ageing popu-
lation than that for a younger population. While only 7.1%
of the total population in Asia is currently more than 65
years old, the proportion of this group is 13.4% in North
America and more than double in Europe (16.4%). Most
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3high-income countries, with the notable exception of the USA
(where growth is largely due to immigration), have sub-
replacement growth rates (electronic supplementary material,
table S1). By contrast, the populations in lower income econ-
omies are growing relatively rapidly. The population growth
rate during the past decade has been highest in Africa fol-
lowed by Asia and Latin America [26]. The population
pyramids of selected countries demonstrate the distribution
of age groups in low- (Bangladesh), lower middle- (India),
upper middle- (China) and high- (Australia, UK, USA)
income countries (electronic supplementary material, figure
S1). As the nature and extents of APIs used by young or
ageing populations are different, so may be their potential
ecological footprints.
(b) Factors influencing consumption patterns of active
pharmaceutical ingredients
The ecological risk associated with an API is dependent
on its consumption volume and pattern of use. Consumption
patterns and overall use of APIs within a country are
influenced by a range of country-specific factors, such as
demographics, economics, disease burdens, government pol-
icies and cultural tendencies. It is important to note that a
greater extent of resources available in high-income nations
allows better monitoring and regulation of API use, compared
with low-income nations.
There is no single method that allows an unbiased assess-
ment of the use of APIs in different nations, let alone the use of
APIs that are used illegally. However, a number of ways of
estimating consumption of APIs within a country has been
attempted. These include marketing data, surveys of APIs dis-
pensations, wastewater data [27], as well as estimation of total
volume available of an API (i.e. sum of manufactured and
imported APIs, minus exported APIs). Regional API consump-
tion has been estimated by monitoring concentrations of APIs
in sewerage systems and ‘back-calculating’ to get a figure relat-
ing to the average consumption in the area serviced by the
sewerage network. This approach has been applied for esti-
mating the usage of illicit drugs [28,29], for example.
However, this approach would become less viable in areas
where connectivity to sewers is low, which is often the case
in low-income countries (electronic supplementary material,
table S1). The other approaches to estimating API consumption
also have their own advantages and disadvantages [27], with
some able to provide a better estimation than others. For
example, while data relating to the sales of APIs in monetary
terms are readily available, this type of information is highly
dependent on a number of variables and is therefore not
easily translatable into the mass of APIs consumed.
Prescription numbers can provide a useful measure,
especially when the amount of API within a prescription is
known. Total volumes sold within a country can similarly
be converted into number of doses consumed within a
country. The use of the defined daily dose (DDD) or DDD
per capita concept, used by the World Health Organization
(WHO), allows a comparative measure that takes into
account the different potency of drugs (in humans) and of
drug consumption between population groups. One down-
fall of estimating inputs into the environment based on
volumes consumed within a country is that adherence to
API therapy, especially for long-term treatment, is around
50% in high-income countries and even less in lowerincome economies [30]. Although this measure may therefore
represent an overestimation of API use, many of these unused
APIs can still be disposed of in a way that will ultimately lead
to environmental contamination [31].
(i) Differences in disease burdens
It is generally accepted that as a country’s population ages, the
demand for APIs increases [32]. Higher levels of urbanization
are associated with changes in lifestyle, along with a higher per
capita income, which is an important factor in the access to and
use of APIs. Increased affluence, through urbanization and
wealth, also influences the pattern of disease burden with a
subsequent occurrence of chronic or non-communicable dis-
eases comprising a higher burden, relative to acute or
infectious diseases, in higher income countries [32]. Some
chronic diseases such as diabetes are becoming prevalent in
a number of lower income countries [32] and APIs will
become an increasingly important mitigating factor in redu-
cing the disease burden. For example, more than 80% of
mortality worldwide attributable to diabetes occurs in low-
and middle-income countries [33]. According to projections
by WHO, the number of deaths due to diabetes will double
between 2005 and 2030. Mass drug administration (MDA) pro-
grammes which target whole communities are being used to
target neglected tropical diseases such as lymphatic filiariasis
and leprosy. These MDA programmes are occurring in
Asian, African, Latin American and Pacific nations [34] and
may result in increasing seasonal discharges of APIs to the
environment [35], resulting in greater exposure and impact
during such campaigns.
(ii) Healthcare policy
Healthcare policy, both internationally and nationally, is also
an important factor in preferential use of APIs. An essential
medicines list (EML) is published biennially by the WHO,
which includes APIs that are determined to be the minimum
number required for basic healthcare needs within a country.
The selection of APIs is based on their efficacy, safety and
cost-effectiveness in treating priority conditions. Individual
countries also publish their own EML, which often includes
additional APIs from the WHO EML. Non-steroidal and
non-opioid analgesics, for example, that are listed in the
WHO EML include acetylsalicylic acid, ibuprofen and para-
cetamol, while the majority of the 100 countries with
published EMLs had at least six APIs listed under this cat-
egory, commonly including diclofenac and indomethacin
[36]. This is reflected in the relatively high proportion of
diclofenac use in a number of countries, within the class of
NSAIDs (figure 1). Inclusion on the EML, however, does
not always reflect use of an API, as some NSAIDs such as
mefenamic acid have been found to be used in a greater pro-
portion in countries such as Indonesia and Pakistan (figure
1). The above adds to the complexity involved in establishing
regional trends in API consumption.
(iii) Economic cost of active pharmaceutical ingredients
Cost may carry a disproportionate weighting in the selection
and use of APIs. Global health expenditure and API use is
highly inequitable, with more than 80% of global expenditure
on APIs occurring in high-income countries which represent
18% of the global population. The median per capita con-
sumption of APIs in 2008 was 1042 standard units of API in
ibuprofen
diclofenac
Bangladesh Pakistan Indonesia
China Thailand Australia
celecoxib
naproxen
etoricoxib
meloxicam mefenamic
acid
Figure 1. The relative proportion and volumes of seven common NSAIDs in some Asian countries and Australia. Note: Each ring represents a logarithmic increase,
with the innermost ring representing 0.1 tonnes and the outermost ring representing 1000 tonnes. (Adapted from McGettigan & Henry [36].)
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4high-income countries compared with 135–214 standard units
(a standardized measure of volume that can be converted to a
DDD) of API in low- and lower/middle-income countries [32].
Out-of-pocket expenses paid by patients in high-income
countries are less than 10% in European countries such as
France, the Netherlands and the UK [32]. Conversely, out-of-
pocket expenses in India range from 83% in rural areas to
77% in urban areas, and 98% of API consumption in Pakistan
is covered by individuals [32]. Many other local factors, such as
procurement and distribution practices and cultural prefer-
ences, will also influence API consumption [32]. In the case
of NSAIDs, for example, the median supply price of diclofenac
is as low as $US 0.0055 per tablet compared with $US 0.033 per
tablet for mefenamic acid [37] which is not reflected in their
proportionate use in Pakistan and Indonesia, in particular
(figure 1). Indeed, in Indonesia, phenylbutazone, mefenamic
acid and piroxicam make up nearly 72% of total NSAID use
[36], which all have higher median supply prices compared
with diclofenac and ibuprofen [37].
(iv) Self-medication and over-prescription
In many lower income countries most APIs can be purchased
without a prescription (so-called ‘self-medication’). WHO
defines ‘self-medication’ as the selection and use ofAPIs by indi-
viduals to treat self-recognized illnesses or symptoms [38]. This
is a common practice in many lower income nations in Asia,
Africa and Latin America, and has been a cause of concern for
WHO for a number of reasons including irrational use of anti-
biotics leading to development of resistance, iatrogenic effects,
allergic reactions and poisoning [39]. For example, a survey of
API dispensation patterns in three community pharmacies of
South India over a two-monthperiod revealed that the ‘Schedule
H Drugs’ (APIs requiring a prescription) were extensively dis-
pensed by these pharmacies without a valid prescription [40].
However, the extent of this practice was highly variable
among the surveyed pharmacies (electronic supplementarymaterial, table S2). In addition to self-medication, over-prescrip-
tion or prescription on perceived patient demand is a problem in
lower income countries [41]. A doctor’s prescribing decisions
may be influenced by other factors including vested interests
(links to pharmacy, brand or manufacturing units) and any
incentives offered by the pharmaceutical industry [41]. This,
however, may not be a problem confined to lower income
countries only.
(v) Veterinary use of antibiotics and other active pharmaceutical
ingredients
Although the focus of this paper is on human APIs, the veter-
inary use of APIs is worth noting as there is often an overlap
between the two. In lower income countries, and especially
those located in Asia, substantial amounts of veterinary anti-
biotics are used, especially in animal husbandry and
aquaculture industries [42,43]. The total number and densities
of livestock in some Asian countries, such as China and
India, can be very high [44,45]. According to theUnitedNations
Food and Agriculture Organization (FAO), some 90% of the
total global aquaculture production comes from Asia, with
the majority of this occurring in China [45]. Alongside the com-
paratively large aquaculture industry in East Asia, a much
broader range of APIs, including antimicrobials and parasiti-
cides, have been reported to be used there within the
industry [42,43]. The potential risks associated with the use of
antibiotics in aquaculture for water quality, aswell as the devel-
opment of microbial resistance, has received considerable
attention in recent years (e.g. [18,43,46]).
(vi) Consumption rates of active pharmaceutical ingredients
With respect to total NSAID use, a recent survey in a number
of Asia-Pacific countries [36] indicates that the usage patterns
(in terms of DDDs/1000/day) in low- or middle-income
countries are generally similar to those in high-income
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5countries (figure 2). Comparatively higher use rates are noted
for countries such as Australia, New Zealand, China (Hong
Kong) and Taiwan. Lower use rates were noted for mainland
China, whereas no data were available for India, Japan and
Korea. A similar survey conducted in 2007 assessing the
usage rates of the antiepileptic carbamazepine [47], shows a
greater gap in the prevalence of use in low- and high-
income countries, where a substantially greater usage rate
is evident in Australia, China (Hong Kong), Japan, Korea,
New Zealand and Taiwan (figure 2).
Overuse or other misuses of antibiotics is a global concern
due to the potential for increasing antibiotic resistance [32]. A
survey on use of antibiotics in Delhi involving 33 000 patients
over a 1-year period in 2008 [49], when compared with
the national-level statistics on dispensed API consumption
in Australia in that year [50], indicated that a number of
similarities may exist between lower middle-income and
high-income countries (electronic supplementary material,
table S3). The comparison revealed that despite significant
differences between usage rates of some antibiotics, the overall
usage rates in Delhi and Australia were similar, with 16.5 and
17.5 DDD/1000/day consumed, respectively (electronic sup-
plementary material, table S3). Similarly, in non-hospitalized
Swedish patients, the use of antibiotics in 2008 totalled 13.53
DDD/1000/day [51]. Caution should be exercised in making
a direct comparison between countries, as the Swedish data
include all antibiotics used, whereas the Australian and New
Delhi data do not. Besides the Delhi survey is unlikely to be
representative of Indian rural population. When the usage
rate of APIs is converted into total volume consumed within
a country [52], however, the trends observed with usage pat-
terns are often reversed (figure 2). For example, although the
usage rates (DDD/1000/day) of diclofenac in Australia, Ban-
gladesh and Pakistan are similar, the number of tonnes of
diclofenac consumed in Bangladesh and Pakistan in 2011were five and 10 times greater than in Australia, respectively
(electronic supplementary material, table S4). Constructing a
clear picture of trends inAPIutilization in lower incomenations,
however, is considerablymore challenging [27]. The same is true
for those high-income countries where national-level statistics
on dispensed APIs are not maintained.
(vii) Non-conventional active pharmaceutical ingredients: the
contribution of complementary and alternative medicines
Populations in the Asia region are much more reliant on
natural remedies than elsewhere in the world. Alternative
therapies using herbal medicines, such as Chinese traditional
medicines or Indian Ayurvedic medicines, are commonly
practiced in Asia. According to WHO [53], 80% of the popu-
lation may rely on complementary and alternative medicines
(CAMs) for primary healthcare, while also becoming increas-
ingly popular in high-income countries. The total sale of
herbal medicine in China was equivalent to US$ 14 billion
in 2005 and the revenue in Western Europe reached US$ 5 bil-
lion in 2003–2004. According to an estimate [54], annual sale
of four key CAMs products in the UK was approximately
£36 million per year with corresponding estimate of usage
of the CAMs ranging from 3 to 32 tons per year (electronic
supplementary material, table S5). The implications of
CAM residues in the environment with respect to ecosystem
health are currently not well understood.
(viii) Shifting global manufacturing base to Asia and other
regions
Some lower income countries are manufacturing APIs for
the international market. The manufacturing activities,
including synthesis of APIs and formulation into doses,
can create point-source problems related to APIs’ residues
through the industrial waste discharges, for example, to
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6the riverine environment [55,56]. The Asian API market is
growing at 10–15%, which is double the rate of the G7
countries [24]. India’s domestic API market is the 14th
largest globally with an annual turnover of US$20 billion
and about 80% of the APIs used in India are produced in
the country [57]. According to an estimate, India supplies
some 22% (in terms of sale value) of the world’s generic
APIs, while about 36% of the total global APIs are exported
by China [58]. Indeed, there has been a gradual yet consist-
ent shift in the global API manufacturing sector over recent
years due to the expansion of low cost manufacturing in
Asia. Contract manufacturing was worth US$22 billion in
2009 and is expected to grow at about 11–12% this year
[59]. While the so-called BRIC countries (Brazil, Russia,
India and China) are considered established contract manu-
facturers, countries such as Vietnam, South Korea and
Bangladesh are rapidly emerging contract manufacturing
destinations for American and European markets [59].
It is also a common practice to discharge untreated or
poorly treated industrial wastewater into domestic waste-
water channels in some Asian countries [60,61]. This is for
at least two reasons, namely the lack of adequate treatment
facilities and/or poor regulatory enforcement. Larsson et al.
[62] and Fick et al. [55] published studies on wastewater
quality from the Patancheru Industrial Estate in Hyderabad,
India. This industrial estate has around 90 units manu-
facturing bulk APIs which collectively produce about
1.5 megalitres of wastewater daily. The treatment plant on
the site mixes the effluent with domestic wastewater to
enhance biodegradation. The water downstream of the treat-
ment plants as well as lakes in the region were found to
contain very high levels of API residues, in the order of
mg l21 [52], as opposed to ng l21 levels commonly reported
in Europe and North America. This is indicative of the ineffi-
cient wastewater treatment as well as unauthorized
discharges [55]. Similar reports are available from other
countries such as China [63], Taiwan [64] and Pakistan [55].
The presence of industrial wastewater in the sewage stream
can be a significant contributor to the environmental load
of APIs not only in lower income nations [60,62], but also
globally [15,65]. A companion paper in this issue [15]
discusses this aspect in the global context and demonstra-
tes the point-source pollution implications of the API
manufacturing sector.(c) Exposure-related factors
Fromhuman therapeuticuse alone, itwouldbe expected that for
manyAPIs the potential environmental loadings would be con-
siderably greater in lower income countries based on the
relatively large populations compared with high-income
nations. The total volume of APIs entering the environment is
not only dependent on the total volume used within a popu-
lation but also the ratio of API that is consumed relative to
total sales, pharmacokinetics, wastewater flows and treatment
efficiency [47,66]. The absence of sewerage systems or rudimen-
tary treatment technologies can significantlyaffectAPI exposure
pathways. Where a high proportion of sewerage connectivity
exists, the entry of APIs into the environment is principally a
point-source issue, with discharge into surface waters. Other
environmental compartments, such as groundwater and the
terrestrial environment, may become proportionately more
impacted in lower income nations where sewer connectivity isless common and reliance on septic systems or use of raw
sewerage for irrigation and fertilization is greater.
(i) Urbanization and sewer connectivity
Despite major improvements in sanitation and the hygiene
situation in lower income countries over two decades
(especially in Eastern Asia), in 2011 there were still about
2.5 billion people that did not have access to improved sani-
tation facilities and close to 15% of the total population
continued to defaecate in the open [67]. Improved sanitation
facilities include flush/pour flush to piped sewer systems,
septic tanks or pit latrines. As shown in the electronic sup-
plementary material, table S1, many countries in Africa and
Asia have half or more of their urban populations without
access to improved sanitation. The pathways of release of
excreta to the receiving environment (and, by inference, resi-
dues of APIs) are complex and unlike those from treated
wastewater effluents in high-income nations.
One of the key factors that differentiates the growing
economies from the high-income nations is the degree of
urbanization and the extent of sewer connectivity. Urban
population centres in high-income nations, being connected
to the sewerage system, produce concentrated waste streams
resulting in a point-source pollution problem. The opposite
(diffuse-source) is usually the case in countrieswith predomin-
antly rural populations and/or where sewer connectivity in
urban areas is low. This has a major implication on the distri-
bution and loadings of APIs in the environment. While the
urbanization in lower income South American countries,
namely Argentina and Brazil, is on par (85–90%) with
high-income countries, the highly populated countries in
Asia (Bangladesh, India, Pakistan and Vietnam) have a
much smaller proportion of population (28–36%) living in
urban centres (electronic supplementary material, table S1).
In terms of sewer connectivity, the contrast between the
lower and high-income countries is again stark. Unlike high-
income nations where more than 90% of the populations are
connected with sewers (e.g. Australia, USA, UK, Japan and
Korea), a much smaller fraction of the populations in lower
income countries is connected to sewerage systems. In several
lower income countries in Asia (e.g. Bangladesh, India, Paki-
stan and Thailand), even the urban population has less than
30% connectivity to sewers (electronic supplementarymaterial,
table S1). Indonesia and Vietnam have extremely low sewer
connectivity of 2% and 4%, respectively, due to their reliance
on septic systems. Some 60–90% of the urban population in
Vietnam, Sri Lanka, Indonesia, Thailand and the Philippines
rely on septic systems [68]. The sum of populations in these
three countries (338 million) is equivalent to about 40% of the
total European population. In South America, connectivity
levels vary from high (more than 80%) in Chile and Peru, to
intermediate (more than 40%) in Brazil, Argentina and Bolivia,
and to low (less than 20%) in ParaguayandGuyana [69,70]. The
low degree of sewer connectivity in lower income countries,
therefore, makes a very different release scenario of APIs in
these countries, in comparison with high-income nations.
(ii) Sewage treatment infrastructure and efficiency
Treatment of sewage or septage (waste stored in septic systems)
from domestic sources or effluents from the API manufacturing
industry may play a major role in determining the extent of
environmental exposure to APIs, as some compounds can be
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7quite effectively removed during treatment. Rojas et al. [71]
found that while some of the APIs (such as acetaminophen
and caffeine) are very susceptible to removal during treat-
ment (near 100%), others (e.g. carbamazepine and diclofenac)
are generally poorly removed (less than 50%). In a recent
study on six wastewater effluents of Argentina, where
sewage treatment is poor or absent, the ratio of caffeine/carba-
mazepine was found to be more than 10 [72]. Treatment
efficiencies of sewage treatment plants (STPs) depend on the
treatment technology employed, the physico-chemical proper-
ties of the APIs and the prevailing operating conditions
[67,69]. In a comparative study on removal efficiencies of
APIs in STPs from Canada, Germany and Brazil, Ternes et al.
[73] found that Brazilian STPs were more effective than the
other two countries, probably because of the warmer con-
ditions prevailing during treatment. While many of the lower
income countries are located in the tropics, the STPs in these
regions may not necessarily be more effective [58].
In lower income countries, the centralized treatment infra-
structures found in Europe and North America may either be
non-existent or ineffective. A study on water quality treatment
efficiency of STPs in Delhi by Jamwal et al. [74] found that the
effluent released from these STPs usually failed faecal coliform
criteria. Furthermore, this study highlighted the fact that only
about 50% of the total design capacity was used by the 17 sur-
veyed STPs, which serviced around 11.7 million people.
Irregular power supply was identified as one of the factors
which may be a common problem in the countries with
poor infrastructure investment in utilities. Similarly, for the
septage collected from septic systems, only a small fraction
of septage is currently treated (0–5%) [68]. The exceptions to
this are Malaysia, where 100% of the septage is treated, and
Thailand (30% treatment). In India, there is no treatment
of the septage from more than 160 million onsite sanitation
systems, which are mainly composed of septic systems [68].(d) Populations contributing to the point-source
pollution
In terms of point source of API residues in the environment, the
average footprint of the urban population could perhaps be
assessed on the basis of sewer connectivity. The contributing
population equivalents (CPEs) to this source can be calculated
as a multiple of three factors: i.e. population  urbanization
fraction  sewer connectivity fraction (electronic supplemen-
tary material, table S1). These CPEs have been compared
against their total population in figure 3. This demonstrates
that many low- and middle-income countries, despite their
huge populations, rank much lower than less populous high-
income nations. For example, Indonesia, Vietnam, Nigeria and
Bangladesh have very low CPEs, with only 1–4% of the total
population contributing to point-source emissions. India has a
much lowerCPE than theUSAdue to the lower extent of urban-
ization and sewer connectivity, where only about 10% of the
urban population contributes to the point source. In fact, with
the exception of Argentina and Brazil, most of the lower
income countries listed in the electronic supplementary
material, table S1, have less than 10% of the total population
contributing to the point-source problem. The lower income
economies of Asia and Africa together have lesser total popu-
lation contributing to the point-source footprint than the USA
alone. This is because many countries in Asia (such as Indone-
sia, Vietnam and Thailand) and Africa (such as Nigeria,
Ethiopia, Democratic Republic of Congo, Tanzania and
Sudan) have less than 10% sewer connectivity for the urban
population [67]. The estimated CPEs for point-source contri-
bution of the top five populous countries of Africa (Nigeria,
Ethiopia, Egypt, Democratic Republic of Congo and South
Africa) are about the same as that of the UK alone. This factor
has not been fully appreciated in the current literature, which
has mainly focused on monitoring of APIs in treated effluents
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8and associated receiving environments. However, this does not
mean the risk to the environment is lower in low- to middle-
income nations, but the pathways of release or the receiving
environments may be very different than those of high-
income countries. This aspect is further discussed in §2e below.
(e) Receiving environments
(i) Surface water
Many lower income countries have major population centres,
with a population of more than 750 000, in landlocked regions
[75]. The two most populous countries in Asia, i.e. India and
China, have the majority of their urban agglomerations in land-
locked areas (electronic supplementarymaterial, table S1).When
treatment levels of sewage discharges are poor in these urban
agglomerations then there is considerable pressure on freshwater
systems. Even in the case where major population centres are
located in coastal regions anddilution rates are considerable, resi-
dues of APIs such as antibiotics can still be measured in water at
relatively high concentrations [46,76,77]. Also, while high
dilution levels occur in marine and some freshwater systems,
association of APIs with sediments can make a significant
contribution to their overall environmental loading [78–81].
It is a common practice in many low- and middle-income
countries to discharge untreated sewage to rivers and other
water bodies, and to use these sewage-affected waters for irri-
gation. According to a study conducted in 71 Indian cities in
2009 [82], only 22% of the total 38 255 megalitres of sewage
generated per day in these cities was treated and 78% of
untreated sewage was disposed of in rivers, lakes and ground-
water. Most of Delhi’s 20 drains and effluent from 17 STPs is
discharged into the Yamuna River and is used for irrigation
downstream. With the exception of the monsoon season, the
river essentially becomes a drain for treated and untreated
wastewater. In Thailand, effluents from septic systems enter
waterways via urban canals and it is estimated that 86% of
sewage and 70% of septage are disposed of in waterways or
on land [68]. In some countries, like Argentina, costal and riv-
erside cities have good sewerage connectivity systems but
sewage is released (mainly raw or poorly treated) through
point sources into the surface receiving waters (i.e. Mar del
Plata, Buenos Aires, Rosario). In Buenos Aires, only 14% of
the total volume of effluent discharged into La Plata River
estuary during 2011 was treated [83].
Discharge of raw sewage is not just a problem for low- and
middle-income nations. Unintentional discharges of raw
sewage may occur in high-income countries due either to the
treatment system not being able to cope with the high flow
of wastewater or floods (e.g. Australia and USA), or through
damage to the infrastructure due to earthquakes (e.g. Japan
and New Zealand). For example, in a recent study on anti-
biotic-resistant bacteria in the waterways of New York,
Young et al. [84] found a strong link between the abundance
of antibiotic-resistant bacteria and sewage-associated bacteria
in Hudson River, indicating the presence of the untreated
sewage. Combined sewer overflow can be a problem in
any large cities with centralized sewage treatment and it is
estimated that some 27 billion gallons of raw sewage and
rainwater is discharged every year into the Hudson River.
(ii) Groundwater
In some lower income countries, which rely heavily on septic
systems for sanitation, groundwater may be impacted byAPIs. Inmany situations, septic systems have open or leaky bot-
toms and are only emptied sporadically. In Indonesia, as much
as 70% of the country’s groundwater contamination is caused
by leaking septic tanks and disposal of septage [68]. Small
inland cities in Argentina are dominated mainly by septic sys-
tems and cesspools mainly diffusely impacting chiefly on
groundwaters. Even where septage from septic systems is col-
lected, the question arises as to where the septage is disposed
of and where the residues of APIs end up. According to a
major study on several Asian countries [68], the management
of septage or the sludge that has accumulated in septic systems
is not a top priority for most countries. The study found that, in
the absence of public services, septage is often collected once in
3–5 years and is disposed of in drains, waterways, open land
and agricultural fields. Clearly, the groundwaters in countries
depending on septic systems are likely to be at a greater risk
of contamination with API residues than in those that are well
connected to a sewerage system.
(iii) Land
It is estimated that about 20 million ha of agricultural
land worldwide is irrigated with wastewater (treated and
untreated) and it is common practice in low- to middle-
income countries to use untreated or heavily polluted
wastewater for irrigation [85]. In dry areas of South America,
treated or poorly treated effluents are commonly used for irri-
gation; for example, primarily treated sewage effluents are
used for irrigation in Mendoza City (Argentina) [86]. API-
contaminated water used for irrigation has led to concerns
related to uptake in plants and soil organisms [87,88], as
well as potential for development and transfer of resistance
genes in soil-based pathogens [89]. Septage collected from
septic systems is often disposed of on open land or agricul-
tural fields [68]. In squatter settlements that are inaccessible
to vehicles, septage may be manually collected and disposed
of close to habitations. The disposal of untreated septage is
generally uncontrolled in many of these countries. Biosolids
collected from STPs or animal manures are applied to land
as fertilizers or soil amendments in some medium- and
high-income nations (e.g. Australia, Japan and China). How-
ever, some other nations (e.g. Korea) do not allow biosolids
or sewage sludge on food producing agricultural lands [90].
The impact of disposal of raw sewage on land has poten-
tial human and ecological health implications through
contamination of food and groundwater.3. Environmental monitoring of active
pharmaceutical ingredients in lower
income countries
(a) Environmental monitoring studies in Asia and
South America
Comparatively few environmental surveys monitoring APIs in
STPs and receivingwaters have been undertaken inAsia-Pacific
countries relative to North America and, in particular, Europe.
A recent comprehensive review of 236 monitoring studies in
peer-reviewed journals undertaken by Hughes et al. [20] high-
lighted this regional bias. For example, from a subset of 155
studies, 16% were based in Asia and, of these, the majority
were based in the Guangdong province of China and mainly
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9included analysis of antibiotic residues [20,79,91]. A bias
towards high-income countries was also noted in a review of
anti-infectives by Segura et al. [6], which found that of 159
papers reviewed, only 16% represented low- to middle-
income countries (which includes China). Along with this
regional/economic bias, it was also noted that there was a dis-
tinct emphasis on monitoring APIs within the therapeutic
categories of the cardiovascular system, anti-infectives (specif-
ically antibiotics), nervous system (including antiepileptics
and analgesics) and the musculoskeletal system (specifically
NSAIDs) [20]. In the case of antiepileptics, this refers in particu-
lar to carbamazepine, which is the most commonly detected
API in Europe and North America and among the most com-
monly represented API in the Asian region (figure 4). Indeed,
Hughes et al. [20] noted that more than 50% of the studies
they reviewed were represented by only 14 APIs. More recent
studies published after this review [20] tend to highlight the
focus on antibiotics within their monitoring programmes
[18,79,91–97]. This is likely to be related to the perceived
irrational use of antibiotics in many Asian countries [79,98]. A
monitoring study on antibiotics in five tropical Asian countries
(India, Indonesia, Vietnam, Malaysia and the Philippines)
found concentrations of sulfamethoxazole that were consider-
ably higher than those reported in Europe, USA, Australia
and Canada [18]. The study estimated that some 12 tons of sul-
famethoxazole was annually discharged from the Mekong
River into the South China Sea. Indeed, similar masses of anti-
bioticswere also estimated to be carried by a numberof rivers in
China, amounting to hundreds of tonnes of combined anti-
biotics likely to be discharged per year [77,99]. With a number
of large river systems present in Asia, such as the Yellow
River with a flow of around 200  108 m3 yr21 considerations
to both comparative concentrations and amounts are important
in estimating potential risks.
The concentrations of the most frequently detected anti-
biotic and non-antibiotic APIs in China are similar to those
in other Asian countries (e.g. Taiwan, Japan and South
Korea), South America [100] as well as the rest of the world
(figure 4) [20,79,91]. While non-antibiotic APIs are generally
at ng l21 concentrations; salicylic acid, ametabolite of acetylsa-
licylic acid or aspirin, has been detected at a number of
locations at low mg l21 concentrations in surface waters [79].
As both salicylic acid and acetylsalicylic acid are highly sus-
ceptible to removal (more than 90%) during wastewater
treatment (especially during secondary and higher treatment)
[101,102], their mg l21 concentrations in surface water may be
indicative of either an extremely high level entering a STP or
of a low efficiency of treatment [103]. In South America
(Argentina and Brazil) also, APIs in surface waters are ubiqui-
tous and residues have been detected in the range from below
the limit of quantitation to about 10mg l21 depending on
the compound and sewage treatment, sometimes several
kilometres downstream of discharge points [94,97–100].(b) Implications for understanding surface water
concentrations of active pharmaceutical ingredients
in Asia
The studies reviewed in §3a, especially those reporting very high
concentrations in surface waters (e.g. [15]) raise two important
points. First, the potential for inputs into surface waters from
manufacturing sources may be disproportionately high relativeto inputs from either human post-therapeutic use or from other
sources, such as veterinary inputs. Second, based on the limited
number of studies available, it is difficult to surmise whether
such extreme levels are indicative of a general trend or not.
This is highlighted by the notable bias in the relatively few pub-
lished monitoring studies, where STPs servicing more densely
populated areas were targeted. This bias is entirely understand-
able since researchers are usually attempting to identifywhether
APIs are also present in their particular region, where there may
be limited or no precedent. Following well-developed sampling
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10protocols, throughmonitoring urbanmunicipal wastewater dis-
charges for a constrained set of target APIs, would therefore be
more likely to reveal similar trends between high- and lower
income countries. Indeed, the concentrations of the most com-
monly targeted APIs can be seen to be reasonably consistent
when comparing between the European, North American and
Asian regions (figure 4). The notable exception is ciprofloxacin,
which is heavily skewed by Indian sites [20,62,104], although
other manufacturing facilities in China, Taiwan and Pakistan
have also contributed to concentrations of antibiotics, analgesics
and NSAIDs being higher than expected [63,64,105]. With the
recent proliferation of manufacturing activity occurring in
countries with a lower quality of water treatment capacity, a
greater number of broadly representative monitoring studies
need to be undertaken to assess environmental concentrations
of APIs in Asia. Representative monitoring would need to take
into account spatial and temporal variations in concentrations of
APIs, sources of inputs and a broader range of APIs [106]. This,
however, remains a challenging goal, considering the number
of years of research effort by relatively well-resourced European
andNorthAmerican laboratories to generate a reasonably limited
representation of marketed APIs that are presently detectable in
surface waters. Furthermore, the focus on monitoring concen-
trations of APIs in aquatic systems in both high- and lower
income nations has resulted in a correspondingly low level of
understanding relating to exposure to APIs in terrestrial ecosys-
tems [7]. Where there has been an assessment of APIs in soils,
the emphasis has been on antibiotics, particularly in sewage
sludge [78,91], which can be used as fertilizer to an appreciable
extent [107,108].4. Implications for ecological risk of active
pharmaceutical ingredients in lower income
countries
The comparison of the limited published monitoring data
currently available in lower income countries does not
suggest a major difference in the average concentrations of
human API residues. There are a number of points, however,
that would suggest this may not be considering the broader
picture of the comparative burden of discharged APIs in
different countries. As was discussed in §3a, the studies tar-
geting APIs in low-income countries have been relatively
few in number and geographically constrained. Furthermore,
the majority of these studies focused on 14 APIs, which is a
substantial under-representation of marketed APIs [20].
This narrow focus would suggest that definitive evidence
for comparative environmental loads of APIs and associated
ecological risks, requires a considerably broader assessment
of the presence of APIs, both in terms of the class of API
and their loadings in geographical regions [106]. The identifi-
cation of obvious differences in use patterns of some APIs
(e.g. [36,47]) and environmental concentrations of APIs [62]
highlights the need for a broader assessment to determine
whether these are anomalies or part of a general trend.
(a) A qualitative assessment of ecological risks in lower
income countries
An integrated assessment based on key factors discussed in
this paper in §§2 and 3 has been summarized in table 1 asa means of estimating the potential extent of API inputs
into the environment, and the implications for ecological
risk, in a selection of low-, middle- and high-income
countries. This table represents a qualitative assessment of a
number of factors that are likely to contribute to the environ-
mental input of APIs, irrespective of class of API, and
includes factors that influence consumption rates, removal
of APIs from wastewater streams post therapy and the general
state of the environment into which APIs may be discharged.
Each factor presented in table 1may also take into consideration
a number of other factors. For example, while sewage connect-
ivity is important for general sanitation, it can also cause
environmental inputs of APIs to shift from a diffuse-source to
point-source situation. Where a point-source situation exists, a
consistently high degree of treatment is necessary to mitigate
entry of APIs into environments receiving discharges. While
the issue of inputs of veterinary APIs was only briefly dis-
cussed, this is highlighted in table 1 as it is likely to represent
an important input of APIs to rural environments, especially
when urbanization can be 50% or less in many low- to
middle-income countries (table 1).
In general, high-income countrieswere the only countries to
have a low-risk rating, while China and India were considered
to have the conditions that would constitute a high ecological
risk fromAPIs. Because each factor was weighted evenly, how-
ever, there was no clear factor, such as income status or
population size, that led to the overall risk level. In the case of
Australia and New Zealand, a relatively small population in
few urban centres, generally discharging highly centralized
STPs into the marine environment meant an overall low-risk
rating. This is despite an ageing population with high public
expenditure on healthcare (electronic supplementary material,
table S1). Although the income, age demographics and sewer
connectivity of China and India differ, they both have high
population pressures, a high proportion of these population
centres based in landlocked regions, a large and rapidlyexpand-
ing API manufacturing industry and a considerable terrestrial
and aquatic livestock density.
It would be expected that a considerably greater degree of
exposure risk exists where high connectivity to STPs with
poor treatment levels leads to highly concentrated effluent
streams entering aquatic ecosystems [55] (table 1). Other
exposure pathways that have limited parallels in high-
income countries also include APIs entering aquatic environ-
ments through diffuse sources of poorly treated wastewater
or through direct application of untreated or poorly treated
wastewater and sludges to terrestrial environments [68]. For
example, a substantial proportion of untreated or poorly trea-
ted sewage is used for irrigation in the Indian subcontinent.
In this region, a greater risk to terrestrial organisms may be
expected [87]. The rapidly growing aquaculture and livestock
industries of China and Southeast Asia (table 1), relying on
the use of antibiotics and anti-infectives [43], is resulting in
a greater exposure of aquatic and terrestrial organisms to
antibiotics [18,46,81,97,119] with implications for the devel-
opment of resistance to antibiotics [104]. Tropical regions of
Southeast Asia (including Indonesia, Malaysia, the Philip-
pines and Thailand), Africa and South America are
recognized biodiversity hot-spots from species richness,
threatened species or endemic species standpoints [120,121].
Some of these regions are also identified as having greater
API footprints in the terrestrial and aquatic environment
(table 1). There is a need for more research in these areas to
Table 1. Summary of the factors that contribute to the potential ecological risk of APIs to aquatic organisms leading to an overall risk rating for selected
countries. Each factor summarizes identified pathways into the environment of APIs, such as use patterns, manufacturing activity, sewage systems, veterinary
inputs and other environmental stressors, for each country. The relative risks are ranked on the basis of low, medium and high and summarized as an overall
ecological risk rating of APIs due to expected exposure levels and the general state of the environment. (Caption overleaf.)
country 
larurnabru
overall state of 
environmentg 
overall 
risk 
ratingh 
urban 
populaon 
(% total 
populaon) 
[75]a 
API 
consumpon 
[48,109]b 
manufacturing 
sector 
[110–112]c 
% sewage 
connecvity/
treatment 
[67] 
receiving 
environment 
[67,75]d 
animal 
populaon 
density 
(terrestrial) 
[44,113] 
aquaculture 
producon 
[113] 
use of 
veterinary 
medicines 
[45,114]e 
use of 
sewage in 
agriculture 
[115–117]f
Argentina 
43 million 
(92%); 
4 cies 
>750 000 
populaon
median age: 31 
upper middle 
income 
API 
manufacturing 
present 
78%; low 
degree of 
treatment 
majority of 
discharge to 
coastal 
environment 
(75% coastal) 
moderate to 
high bovine, 
low poultry, 
low swine 
density 
0.003 × 106 
tonnes 
produced 
moderate 
animal density, 
aquaculture 
producon 
yes; high 
volume of 
water reuse, 
moderate level 
of treatment
rank 93rd EPI 
low level of water 
stressc; 
low/moderate 
threat to water 
security d 
medium 
Australia 
20 million 
(89%); 
5 cies 
>750 000 
populaon
median age: 38 
high income 
API export value 
US$1–5 billion 
(2009) with 
~15% growth 
(2001–2009)
>90%; high 
degree of 
treatment 
majority of 
discharge to 
coastal 
environment 
(100% coastal) 
moderate 
bovine, 
low poultry, 
low swine 
density 
0.07 × 106 
tonnes 
produced
low animal 
density; CAFOsi 
[118] present 
yes; high 
volume of 
water reuse, 
high level of 
treatment
rank 3rd EPI 
high level of 
water stress; 
low/moderate 
threat to water 
security
low
Bangladesh 
43 million 
(28%); 
4 cies 
>750 000 
populaon
median age: 24 
low income 
API 
manufacturing 
present 
11%; low 
degree of 
treatment 
majority of 
discharge to 
coastal 
environment 
(100% coastal) 
low bovine, 
moderate to 
high poultry, 
low swine 
density 
1.5 × 106 
tonnes 
produced 
high poultry 
density and 
aquaculture 
producon 
no data; poor 
level of 
treatment if 
used 
rank 169th EPI 
high level of 
water stress; high 
threat to water 
security
medium
Brazil 
166 million 
(85%); 
26 cies 
>750 000 
populaon
median age: 30 
upper middle 
income 
API 
manufacturing 
present 
72%;low 
degree of 
treatment 
majority of 
discharge to 
inland 
environment 
(42% coastal) 
moderate to 
high bovine, 
moderate 
poultry, low 
swine density 
0.63 × 106 
tonnes 
produced 
moderate 
animal density 
and 
aquaculture 
producon 
yes; high 
volume of 
water reuse, 
moderate level 
of treatment 
rank 77th EPI 
low level of water 
stress; low/high 
threat to water 
security
medium
China 
681 million 
(51%); 
143 cies 
>750 000 
populaon
median age: 36 
upper middle 
income 
API export value 
>US$5 billion 
(2009) with 
~20% growth 
(2001–2009) 
74%; low 
degree of 
treatment 
moderate 
discharge to 
inland 
environment 
(44% coastal) 
low to high 
bovine, low to 
high poultry, 
low to high 
swine densityj 
38.6 × 106 
tonnes 
produced 
high animal 
density and 
aquaculture 
producon 
yes; high 
volumes of 
reuse, poor 
level of 
treatment 
rank 118th EPI 
low/high level of 
water stress; high 
threat to water 
security
high
India 
388 million 
(31%); 
57 cies 
>750 000 
populaon
median age: 27 
lower–middle 
income 
API export value 
~US$5 billion 
(2009) with 
~20% growth 
(2001–2009)
33%; low 
degree of 
treatment 
majority 
discharge to 
inland 
environment 
(37% coastal)
high bovine, 
moderate 
poultry, 
 low swine 
density 
4.6 × 106 
tonnes 
produced 
high bovine 
density and 
aquaculture 
producon 
yes; high 
volumes of 
reuse, poor 
level of 
treatment
rank 155th EPI 
high level of 
water stress; high 
threat to water 
security
high
Indonesia 
123 million 
(51%); 
15 cies 
>750 000 
populaon
median age: 29 
lower middle 
income 
API 
manufacturing 
present 
2%;high 
reliance on 
sepc tanks 
majority 
discharge to 
coastal 
environment 
(100% coastal) 
low bovine, 
high poultry, 
low swine 
density 
2.7 × 106 
tonnes 
produced 
high bovine 
density and 
aquaculture 
producon 
no data; poor 
level of 
treatment if 
used
rank 112th EPI 
low/moderate 
level of water 
stress; high threat 
to water security
medium
Japan 
115 million 
(91%); 
8 cies 
>750 000 
populaon
median age: 46 
high income 
high value of 
producon 
(~US$67 billion 
in 2007) 
>95%; high 
degree of 
treatment 
majority 
discharge to 
coastal 
environment 
(88% coastal) 
moderate 
bovine, 
high poultry, 
low swine 
density 
0.56 × 106 
tonnes 
produced 
high poultry 
density and 
moderate 
aquaculture 
producon 
yes; high 
volume of 
water reuse, 
high level of 
treatment
rank 26th EPI 
low/moderate 
level of water 
stress; low threat 
to water security
medium
Korea
(Republic) 
40 million 
(83%); 
13 cies 
>750 000 
populaon
median age: 40 
high income 
high value of 
producon 
(~US$21 billion 
in 2007) 
87%; high 
degree of 
treatment 
majority 
discharge to 
inland 
environment 
(30% coastal) 
moderate to 
high bovine, 
high poultry, 
moderate 
swine density 
0.51 × 106 
tonnes 
produced 
high animal 
density and 
moderate 
aquaculture 
producon
no
rank 43rd EPI 
low level of water 
stress; 
moderate/high 
threat to water 
security
medium
New 
Zealand 
3.8 million 
(86%); 
1 city >750 000 
populaon
median age: 37 
high income 
API 
manufacturing 
present 
>95% (1990 
data); high 
degree of 
treatment 
majority 
discharge to 
coastal 
environment 
(100% coastal) 
moderate 
bovine, 
low poultry, 
low swine 
density 
0.11 × 106 
tonnes 
produced 
moderate 
bovine density 
and 
aquaculture 
producon 
no
rank 16th EPI 
low level of water 
stress; low threat 
to water security
low
Philippines 
46 million 
(49%); 
4 cies 
>750 000 
populaon 
median age: 23 
lower middle 
income 
API 
manufacturing 
present 
37%; low 
degree of 
treatment 
majority 
discharge to 
coastal 
environment 
(100% coastal) 
moderate 
bovine, 
moderate 
poultry  
low swine 
density 
0.77 × 106 
tonnes 
produced 
moderate 
animal density 
and 
aquaculture 
producon 
no data; poor 
level of 
treatment if 
used
rank 114th EPI 
low level of water 
stress; high threat 
to water security
medium
Singapore 
5 million 
(100%); 
1 city >750 000 
populaon 
median age: 34 
high income 
API 
manufacturing 
present 
100%; high 
degree of 
treatment and 
reuse 
Majority re-use 
(100% coastal) 
low bovine, 
high poultry, 
low swine 
density 
0.004 × 106 
tonnes 
produced 
high poultry 
density and low 
aquaculture 
producon 
ny agricultural 
base, high level 
of treatment
rank 4th EPI 
low level of water 
stress; high threat 
to water security
low
Sweden 
8 million (85%); 
1 city >750 000 
populaon 
median age: 42 
high income 
high value of 
producon 
(~€6.5 billion in 
2011) 
83%;high 
degree of 
treatment 
majority 
discharge to 
coastal 
environment 
(100% coastal) 
low bovine, 
low poultry, 
low swine 
density 
0.013 × 106 
tonnes 
produced 
low animal 
density and 
aquaculture 
producon 
yes
rank 9th EPI 
low level of water 
stress; low threat 
to water security
low
Thailand
24 million 
(34%); 
2 cies 
>750 000 
populaon 
median age: 42 
upper middle 
income 
API 
manufacturing 
present 
9%; high 
reliance on 
sepc tanks 
majority 
discharge to 
coastal 
environment 
(100% coastal)
moderate 
bovine, 
moderate 
poultry, 
low swine 
density
1 × 106 tonnes 
produced
moderate 
animal density 
and high 
aquaculture 
producon
yes
rank 78th EPI 
low level of water 
stress; 
moderate/high 
threat to water 
security
medium
UK
50 million 
(80%); 
7 cies 
>750 000 
populaon 
median age: 40 
high income
high value of 
producon 
(~€20 billion 
2011) 
>95%; high 
degree of 
treatment 
moderate 
discharge to 
inland 
environment 
(55% coastal) 
moderate to 
high bovine, 
low poultry, 
low swine 
density 
0.18 × 106 
tonnes 
produced 
moderate 
bovine density 
and 
aquaculture 
producon 
no
rank 12th EPI 
low level of water 
stress; 
low/moderate 
threat to water 
security
medium
USA
43 million 
(82%); 
4 cies 
>750 000 
populaon 
median age: 37 
high income 
high value of 
producon 
(~US$179 billion 
in 2007) 
>95%; high 
degree of 
treatment 
moderate 
discharge to 
inland 
environment 
(56% coastal) 
moderate to 
high bovine, 
low to high 
poultry, 
low to high 
swine density 
0.4 × 106 
tonnes 
produced 
low/high 
animal density 
and 
aquaculture 
producon; 
CAFOs present 
yes; high 
volume of 
water reuse, 
high level of 
treatment
rank 33rd EPI 
low/high level of 
water stress; 
low/moderate 
threat to water 
security
medium
Vietnam 
28 million 
(31%); 
5 cies 
>750 000 
populaon 
median age: 29 
lower middle 
income 
API 
manufacturing 
present 
4%; high 
reliance on 
sepc tanks 
majority 
discharge to 
coastal 
environment 
(100% coastal) 
moderate 
bovine, 
high poultry, 
moderate 
swine density 
2.8 × 106 
tonnes 
produced 
moderate to 
high animal 
density and 
high 
aquaculture 
producon 
yes; high 
volumes of 
reuse, poor 
level of 
treatment
rank 136th EPI 
moderate level of 
water stress; high 
threat to water 
security
medium
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aThe ranking has been based on a combination of level of urbanization, total urban population and number of cities with population more than 750 000.
bBased on medicine consumption in high-income countries approximately 2 times greater than upper-middle, approximately 5 times greater than lower-middle
and approximately 10 times greater than low income [32].
cThe ranking has been based on degree of treatment, while sewage connectivity relates to extent of concentration of contaminants in receiving environment.
dThe percentage discharge relates to the geographical location of major cities (population more than 750 000), although this does not preclude into marine/
estuarine discharge of wastewater for landlocked urban centres or freshwater/land discharges for coastal urban centres. A higher likelihood of coastal discharge
suggests a higher degree of contaminant dilution in marine ecosystems.
eThe ranking of the use of veterinary medicines was based on animal density and volumes of aquaculture production.
fRanking is based on level of treatment and volume of use.
gWater stress relates to annual average water scarcity in major river basins 1996–2005. Water security relates to cumulative impact of 23 factors on water resources.
hOverall ranking: red¼ 3, amber ¼ 2, green ¼ 1; overall score: 10–16¼ low risk, 17–24 ¼ medium risk, more than 24¼ high risk.
iCAFO ¼ Concentrated animal feeding operation; an agricultural operation where animals are fed and raised in confined situations.
jHigh density relates to eastern China.
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12develop a better understanding of potential impacts of APIs
on the biodiversity of these unique and fragile ecosystems.
Despite being a qualitative assessment, the rating frame-
work used in table 1 may be a useful way of comparing the
current relative risks that APIs are likely to pose to the
environment and focus future research efforts. As these econ-
omies grow further, some of the risk factors may be
downgraded, whereas others may be upgraded. For example,
the increasing urbanization occurring in many low- to
middle-income countries presents two potential outcomes;
increased urbanization can lead to the development of
point sources of APIs, along with other pressures on sur-
rounding environments, while on the other hand, greater
urbanization can lead to greater wealth and subsequent
investment in infrastructure and sanitation to mitigate
more effectively inputs of APIs. In combination with other
proposed strategies for targeting relevant APIs in particu-
lar countries, this rating framework could contribute to
more effective allocation of resources for the assessment of
potential risks of APIs.
(b) Observations on ecological risks in lower income
countries
The majority of published literature relating to lower income
countries has focused only on the environmental exposure
aspects of APIs. Indeed, as discussed in §2c, it is primarily
the exposure that is likely to be different in these countries
(e.g. volume and type of APIs used, lack of treatment facili-
ties, differences in the size and nature of sources). However,
a number of examples, mainly from China and India, demon-
strate the comparatively high environmental risk that can
occur due to the levels of exposure. Analysis of surface
water samples collected in northern China, in conjunction
with a review of predicted no-effect concentrations for sensi-
tive species, showed that measured concentrations of 11 of 14
anti-infectives represented a high risk at least once at 13
different sites [119]. Three anti-infectives had concentrations
that were considered to be a high risk at all 13 sites. More
generally, the highest measured concentrations of two anti-
infectives, sulfamethoxazole and ofloxacin, in wastewater
and natural waters reviewed in three different regions
(Europe, North America and Asia) were at levels close to,
or overlapping, lowest observable effect concentrations
(LOECs) or 50% effective concentrations (EC50) [6]. While
overlap with LOECs and EC50 values was more significantin undiluted wastewater samples, the authors suggested
that even a weak overlap could have an important impact
on the most sensitive species (such as bacteria and algae),
as well as contributing to the development of anti-infective
resistance [6]. Even in the case where effects specific to a par-
ticular mode of action (e.g. effects of antibiotics on
microorganisms) are not evaluated, the risks to aquatic
organisms can still be high. One of the few examples that
assessed the ecotoxicity of wastewaters in a lower income
country, containing high (mg l21 to mg l21) concentrations
of a range of APIs, demonstrated that clear effects occur
during the developmental stages of frogs (Xenopus tropicalis)
and fish (Danio rerio), even at 1 in 500 dilutions of the effluent
[122]. Slightly lower dilution levels of this effluent sourced
from Indian API manufacturers also had effects on microbes
(Vibrio fisheri), invertebrates (Daphnia magna) and plants
(Lactuca sativa) [62].
As noted in §3a, it is difficult to determine whether the
comparatively high concentrations measured in a limited
number of studies in lower income countries are representa-
tive of a general trend [6,20]. Based on the summary of risk
factors presented in table 1, large urban populations were
considered to represent a high-risk situation where pharma-
ceuticals are released in concentrated streams to receiving
aquatic environments. This is particularly the case where
there is a high degree of sewage connectivity with a poor
level of treatment, as is the case in Argentina, Brazil and
China (table 1). The relative impacts of APIs derived from
wastewater are also expected to be greater in freshwater sys-
tems, compared with marine systems, where there is a lesser
degree of dilution or spatial accumulation of impacts [115].
There is, however, a substantial knowledge gap associated
with exposure and effects of APIs in marine ecosystems
[123], although the exposure factors that have been raised
here would suggest a greater relative risk would occur in
lower income countries. This is due to factors such as poor
wastewater treatment in urban coastal environments and a
high volume of aquaculture production, which is especially
concentrated in Asian countries (table 1).
So far, comparatively little research has been conducted
on environmental fate and exposure of APIs in terrestrial sys-
tems, let alone their ecological impacts. Many terrestrial
studies relating to toxicity of APIs mainly focus on veterinary
APIs, such as antibiotics and parasiticides, which relate to
their post-therapeutic use in livestock [124]. It is also recog-
nized that the application of wastewater or sludge on land
rstb.royalsocietypublishing.org
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13can also contribute to APIs entering terrestrial environments
where they can be taken up by plants but their ecological
implications are unclear [125]. It is likely, however, that the
release of APIs through the disposal of poorly treated waste-
water and sludges on land may lead to a greater extent of
exposure in lower income countries.
Indeed, it is likely that the exposure of organisms in all
receiving environments are generally going to be at higher
levels in a number of lower income countries than that experi-
enced in high-income countries. This, however, will not be in
isolation from other environmental stressors, including over-
all pollution, unsustainable water use and rapid urbanization,
which have contributed to a global decline in biodiversity
[115,126]. In lower income countries, such environmental
stressors are likely to be considerably greater than in high-
income nations [115–117], which will decrease the ecological
resilience for coping with the additional burdens of API
contamination. 9:201305865. Concluding remarks
From the preceding discussion, it is clear that the situation of
APIs in the environment in lower income countries is likely
to be quite different than in higher income countries. While
78% of the world’s population lives in Asia and Africa
(mostly in lower income nations) the high population pressure
does not directly translate to greater impact of APIs on the
environment. In addition to factors such as population
density, a myriad of other factors, such as sanitation and
hygiene, urbanization and sewer connectivity, treatment
chain or lack of it, and the presence of an API manufacturing
sector can influence the relative footprint of APIs in these
countries. The lack of data on environmental occurrence in
emerging economies in comparison to developed countries
makes it difficult to understand the exposure pathways andpresence of residues of APIs in the environment in lower
income countries.
The use of many herbal medicines and natural products,
common in Asia, has been demonstrated to have implications
for toxicity based on their biological activity or through inter-
actions with other medicines in the realm of human therapy
(e.g. [126,127]). These traditional or herbal medicines can con-
tain a vast array of biologically active ingredients, either
identified or unidentified [128], sometimes in conjunction
with conventional APIs [129]. The potential impact of comp-
lementary and alternative medicines on the environment into
which they are released is, therefore, unknown and should be
taken into consideration in future assessments of environmental
risks from APIs [8].
The pace of development in many of the lower income
countries is likely to lead to greater wealth, access to the
healthcare system and greater spending on healthcare,
improvement in sanitation and hygiene and connectivity to
centralized sewerage systems in coming years. This would
mean there is likely to be a rapid convergence towards a
point-source nature of dispersals of APIs in the environment
in lower income countries. In the meantime, the increasing
global attention being directed towards the issue of APIs in
the environment may facilitate research, development and
understanding of the risks associated with these compounds
and may help the lower income nations more effectively to
allocate resources to better manage the problem.Acknowledgements. We are grateful to Dr Min Qiao of the Chinese Acad-
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